UKMI Q&A for branded prescribing recommendations states that fentanyl patches are available as matrix and reservoir formulations; Patient familiarity with one brand is important. Generic prescribing is therefore not recommended and is considerably more costly. Matrifen (matrix) was agreed as a cost effective brand for primary care prescribing and is currently the most commonly prescribed brand of fentanyl patch amongst the Surrey CCGs. Mezolar matrix patches and Mylafent patches are similarly lower cost. Note: patches must not be cut because damage to the rate-limiting membrane can lead to a rapid release of fentanyl resulting in overdose. If the prescriber intends the patch to be cut (NB: unlicensed and not recommended by the MHRA) then the prescription must specify a brand of matrix formulation patch.

Fentanyl patches have a very limited place in therapy in persistent non-malignant pain and should only be prescribed on advice of a relevant specialist (e.g. renal physician).

Brand name prescribing is recommended to reduce the risk of confusion and error in dispensing and administration. Please refer to recommendation made by the MCG (below) in November 2015.

Fentanyl patches should not be prescribed under any circumstances for opioid naïve patients. Take care with the calculation of dose equivalents.

Please refer to the Persistent non-malignant pain guidelines and supporting resources below for further information